Palatin Forum: Community User: allesaufaurora

https://palatin.com/press_releases/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2-diabetic-nephropathy/ Das hier sind die letzten offiziellen News, seit dem ist die Aktie am steigen.

Mal eine Frage an die Gruppe, da ich Newbie bin. Wieso geht die Aktie die letzten Tage so ab, aber wenn man sich die Kurve des Jahres oder Monats ansieht, ist das Teil eigentlich Schrott. Verstehe das nicht ganz und würde bin hin- und hergerissen da Kohle reinzubuttern.

Ich würde halten. Meine Hoffnung ist ja, dass die Bude irgendwann aufgekauft wird

Mein Gott, es lebt noch ! (immerhin ein Kandidat für meinen Verlustverrechnungstopf 2024) Also doch nicht verkaufen???

https://finance.yahoo.com/news/palatin-reports-positive-phase-2b-124126047.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAGIwgrugF7VqMsfhNDVxksEctjKr_8lHJADJzY9Tu8JrnLMdo4W-fvW5b__Rj9I0N3SxZLT2eC3OIPVGtx1iWVtM8-oaUk9IwkDHBHB70G_IRq-yhzBC4mYgwajlIS1U8whiVA8Hwe3SezYxENhiEZ1NKaTw2lgQZAuwMT17HvhC

Sind das Einstiegskurse oder geht's noch weiter zurück?

Oh my god... Harakiri

Mit dem Begriff Kosmetik hab ich bei PLT kein Problem das trifft es ganz gut. Wenn man sich nur mal die letzten vier Wochen anschaut, gabs öfters mal +15 bis +25%, um dann einen Tag später wieder ebenso stark zu korrigieren.

Ist der Kursanstieg nicht nur Kosmetik? Palatin benötigt doch Geld...in ein paar Tagen geben sie dann neue Aktien aus

Aber man sollte immer direkt auf der HP von PLT schauen. Da steht heute: “Our objective is to out-license the UC program. At this stage, there has been significant interest in and ongoing discussions around our UC program from multiple parties.” Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes inflammation in the digestive tract and can result in damage to the colon lining.2 Patients often experience a range of unpredictable symptoms that impact their daily lives, such as abdominal pain, bloody stool and urgency to use the bathroom.2,3 The disease course varies between patients, and in some cases can lead to surgery or complications, including cancer or death.3,4 Orally administered PL8177 targets melanocortin-1 receptors on the luminal surface of colon epithelial cells. In a Phase 1 clinical study, the oral formulation successfully demonstrated sustained delivery of PL8177 to the lumen of the colon with no systemic exposure. The Phase 2 PL8177 study is a multi-center, randomized, double-blind, placebo-controlled, adaptive design, parallel group of PL8177, with once daily (QD) oral dosing in adult UC subjects for 8 weeks. The study was originally designed to enroll up to 28 adult subjects with active UC from multiple sites, with an interim analysis planned after completion of 12-16 subjects. Due to the strategic decision to out-license the UC program at an earlier stage, Palatin decided to end enrollment after 13 subjects. The efficacy evaluations and endpoints are in line with the latest FDA Draft Guidance for Industry: Ulcerative Colitis: Developing Drugs for Treatment (April 2022), including the primary efficacy endpoint measurement, the Mayo Endoscopic Subscore, which evaluates the level of disease in the colon mucosa. Additional trial information, including inclusion and exclusion criteria, can be found at https://clinicaltrials.gov/ via the identifier NCT05466890. The Company’s Phase 2 trial in UC builds upon presented preclinical data from a series of oral PL8177 dose-ranging studies in the dextran sulfate sodium (DSS) colon inflammation model, which showed significant improvements in inflamed colon health, including relative increases in colon cells needed for a healthy colon. PL8177 treatment showed clear evidence of resolving pathological inflammation by repolarizing colon macrophages from a pro-inflammatory to a pro-inflammation resolving state.

Hier ist so gut wie nix zu erfahren

Gibt's eine Erklärung?

Nächster Anlauf... 🤞🏻

We believe the pharmacological treatment of obesity is in the early stages of a multiyear cycle of innovation and will have a market value greater than $100 billion per year. We do have large companies that are very interested in the dry eye disease programs and then we have -- as well as the glaucoma and retinal. So it may be a mixture. You may see a out-licensing of dry eye disease and then a corporate -- and a corporate combination of assets for the others that are a little bit earlier. Our expectation, not Nostradamus-confirmed, is that we're going to have multiple deals as we go forward. And some of them could be absolutely as early as the first quarter of next year.

As of September 30, 2024, Palatin's cash and cash equivalents were $2.4 million. Palatin did receive a scheduled $2.5 million deferred payment in November 2024 from Cosette Pharmaceuticals related to the sale of Vyleesi. Obviously, since this was received in November, it is not included in our September 30 cash and cash equivalents balance. Future investment and activities will be focused and limited to our core programs in obesity. We've retained an investment bank to conduct, explore and evaluate strategic options for our non-obesity programs. At this stage, there is significant interest in and ongoing discussions for our Phase III dry eye disease program, our early-stage glaucoma and retina development programs and our Phase II ulcerative colitis program from multiple parties.